This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Global Diversity and Inclusion at Royal Dutch Shell (A) and (B), Teaching Note
Sucher, Sandra J.Teaching Note HBS-612023-ETeaching Note for 610-056, 611-051 and 613063.Starting at €0.00
-
Enbos
Bol, J.; Ribera, JaumeCase P-1060Service and Operations ManagementEnbos era la sucesora de una empresa holandesa de titularidad estatal parcialmente privatizada en 1994, aunque el Estado continuó controlando el precio de la energía y el mercado geográfico al que se podía suministrar. A partir de 2003, el sector energético se privatizaría totalmente, por lo que las empresas tendrían que competir por los clientes. El director del proyecto de implementación y desarrollo del software organiza y controla el equipo n...Starting at €8.20
-
Enbos
Bol, J.; Ribera, JaumeCase P-1060-EService and Operations ManagementEnbos was the successor to a state-owned Dutch energy company that was partly privatized in 1994, although the state continued to control energy prices and the geographic market to which it could be supplied. From 2003 the energy sector would be wholly privatized and companies would have to compete for customers. The leader of the software implementation and development project at Enbos organizes and supervises the team whose job is to deal with ...Starting at €8.20
-
Building an Integrated Biopharma Company: Crucell (A)
Hamermesh, Richard G.; Van Der Steen, Marianne; Harmeling, Susan S.Case HBS-815085-EEntrepreneurshipBy 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space, had begun to attract the attention of much larger pharmaceutical companies. While there was much appeal to working with these companies, these relationships could also challenge Cruc...Starting at €8.20
-
The Access to Medicine Index (A): Engaging Stakeholders and Attracting Funding
Afshin Mehrpouya; Diane-Laure Arjalies; Ken MarkCase IVEY-9B17M010-EStrategyThe founder of the Access to Medicine Foundation, based in the Netherlands, had a goal to research and publish a biannual, global survey of pharmaceutical companies and their rankings, in terms of their effects in providing needed medicines to people in developing countries. When the first two iterations of the Access to Medicine Index (ATMI) were published in 2008 and 2010 (see case A), the most prominent challenges were engaging stakeholders—go...Starting at €8.20